CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial

The rate of long-term remissions after treatment of peripheral T cell lymphomas (PTCL) with standard CHOP-like protocols is unsatisfactory. A prospective multicenter phase II trial was initiated in untreated patients with PTCL of all International Prognostic Index-risk groups, evaluating alemtuzumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Binder, C., Ziepert, M., Pfreundschuh, M., Dührsen, U., Eimermacher, H., Aldaoud, A., Rosenwald, A., Loeffler, M., Schmitz, N., Truemper, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790248/
https://www.ncbi.nlm.nih.gov/pubmed/23978945
http://dx.doi.org/10.1007/s00277-013-1880-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790248/
https://www.ncbi.nlm.nih.gov/pubmed/23978945
http://dx.doi.org/10.1007/s00277-013-1880-4

Ejemplares similares